bioRxivImmunologyPreprint
AI recognizes convergent somatic hypermutation signatures to allow the discovery of variant-resilient broadly neutralizing antibodies
Qihong YaniD, Xiaohan HuangiD, Banghui LiuiD, Yicheng Yao, Huiran Zheng, Yidong SongiD, Fandi WuiD, Zhiyun HeiD, Shaowei LiiD, Fangli Chen, Chuanying Niu, Zimu LiiD, Hang YuaniD, Yuting LiniD, Lan CheniD, Na Zang, Juxue Xiao, Tingting WangiD, Canjie Chen, Haoshi Bai, Jia Li, Meng‐Yu WuiD, Jingxian ZhaoiD, Jianhua YaoiD, Yuedong YangiD, , Jincun ZhaoiD
Abstract
Elucidating the mechanisms by which broadly neutralizing antibodies (bnAbs) develop to confer durable immunity in humans is pivotal for the rational design of next-generation vaccines and therapeutics. VH3-53/3-66-encoded public antibodies are widely elicited in the population after the COVID-19 pandemic. Here, we isolated 15 VH3-53/3-66-encoded bnAbs from elite neutralizers who experienced sequential SARS-CoV-2 Omicron breakthrough infections. These bnAbs exhibit exceptional potency and breadth against circulating variants and, as members of a long-lived public antibody lineage, likely contribute to durable humoral protection. Genetic analysis of VH3-53/3-66-encoded bnAbs reveals a convergent somatic hypermutation pattern at seven positions in and around the CDR loops that emerges with repeated viral exposures and distinguishes them from non-bnAbs. Grafting these combined mutations onto clinically escaped antibodies broadens their breadth and restores neutralization activity. Structural analysis shows that these convergent mutations cooperatively remodel CDRs to bind and tolerate virus receptor-binding domain mutations. Using an AI-based antibody language model trained on data linking somatic hypermutations to binding affinity and neutralization, the model is able to identify mutational patterns predictive of breadth, enabling the discovery of a rare bnAb with protective activity against the latest variants from early-pandemic antibody repertoires. This demonstrates the feasibility of establishing an AI-empowered pipeline to identify mutation-tolerant bnAbs from early-pandemic antibody repertoires to fight fast-evolving newly introduced viruses.
- organism: human
- assay: proteomics
- research focus: drug response / drug discovery
- approach: deep learning
- Citations
- 3
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Convergent IGHV3-53/3-66 antibodies elicited by Omicron BA.1 infection broadly neutralize emerging SARS-CoV-2 variants
Naveenchandra Suryadevara, Seth J. Zost, … James E. Crowe·bioRxiv·Aug 20, 2026
- Breakthrough infection elicits hypermutated IGHV3-53/3-66 public antibodies with broad and potent neutralizing activity against SARS-CoV-2 variants including BQ and XBB lineages
- Structural determinants of IGHV1-69 public antibodies conferring resilience to SARS-CoV-2 antigenic escape
Chuanying Niu, Xiaohan Huang, … Xiaoli Xiong·bioRxiv·Mar 23, 2026
- Somatic evolution of a cross-reactive germline antibody that expands its breadth to neutralize new SARS-CoV-2 variants
Huibin Lv, Ziqi Feng, … Chris Ka Pun Mok·bioRxiv·Mar 25, 2026
- Potent SARS-CoV-2 neutralizing antibodies selected from a human antibody library constructed decades ago
M. Qiang, P. Ma, … R. A. Lerner·bioRxiv·Nov 6, 2020
- Fortuitous Somatic Mutations during Antibody Evolution Endow Broad Neutralization against SARS-CoV-2 Omicron Variants
J. Wu, Z. Chen, … Q. Wang·Cell ReportsPeer-reviewed·May 1, 2023